Literature DB >> 1588291

VLA-4-fibronectin interaction is required for the terminal differentiation of human bone marrow cells capable of spontaneous and high rate immunoglobulin secretion.

E Roldán1, A García-Pardo, J A Brieva.   

Abstract

Human bone marrow (BM) is a relevant site for immunoglobulin (Ig) generation in vivo. The occurrence of BM cells capable of spontaneous and high rate Ig secretion for 14 d in vitro has been described previously. Accordingly, these cells provide a suitable model for studying terminal B cell maturation within the BM. We have reported recently that these BM cells are not totally differentiated when isolated from the body, as they require inductive signals from adherent stromal BM cells to complete their maturation. Interleukin (IL)-6 produced by these adherent BM cells was identified as one such signal. The present work shows that IL-6 was necessary, but not sufficient, for the induction of BM Ig-secreting cells, since the cytokine was unable to restore missing IgG in nonadherent BM cell cultures. Supernatants (SN) obtained from cultures of stromal adherent BM cells, either freshly isolated or derived from long-term BM culture (LTBMC), restored Ig secretion by nonadherent BM cells, suggesting that additional soluble factors from BM stromal cells were required. Fibronectin (FN) was identified as that factor, as can be deduced from the following findings: (a) stromal, but not nonadherent, BM cells constitutively produced FN; (b) anti-FN antibodies markedly reduced the IgG secretion in cultures of BM mononuclear cells (BMMC), and blocked the inductive effect of stromal cell SN on nonadherent BM cells, and such a blockade could be reversed by exogenous FN; and (c) finally, although neither IL-6 nor FN alone exerted any effect, the combination of both factors induced optimal Ig secretion by nonadherent BM cells. Furthermore, VLA-4 molecules seemed to be the FN receptor that was active in this culture system, as indicated by: (a) BM Ig-secreting cells exhibited the phenotype VLA-4+ VLA-5-; (b) mAbs directed to VLA-4 (anti-CD29 and anti-CD49d), but not those directed to other adhesion molecules, inhibited Ig secretion by BMMC cultures, and this effect was reversed by FN; (c) the inductive role of the entire FN molecule could be replaced by a fragment containing the CS-1 region, but not by a fragment containing the RGDS sequence; and (d) only mAbs anti-CD49d capable of blocking VLA-4-FN interaction inhibited induction by either the FN or the CS-1-containing fragment of FN.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1588291      PMCID: PMC2119256          DOI: 10.1084/jem.175.6.1739

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  52 in total

1.  Human in vivo-induced spontaneous IgG-secreting cells from tonsil, blood and bone marrow exhibit different phenotype and functional level of maturation.

Authors:  J A Brieva; E Roldán; M L De la Sen; C Rodriguez
Journal:  Immunology       Date:  1991-04       Impact factor: 7.397

2.  Immunoglobulin synthesis by human lymphoid tissues: normal bone marrow as a major site of IgG production.

Authors:  R McMillan; R L Longmire; R Yelenosky; J E Lang; V Heath; C G Craddock
Journal:  J Immunol       Date:  1972-12       Impact factor: 5.422

Review 3.  Adhesive protein receptors on hematopoietic cells.

Authors:  M E Hemler
Journal:  Immunol Today       Date:  1988-04

4.  Limiting dilution analysis of the B cell compartment in human bone marrow.

Authors:  T Hibi; H M Dosch
Journal:  Eur J Immunol       Date:  1986-02       Impact factor: 5.532

5.  Interleukin 6 is essential for antibody secretion by human in vivo antigen-induced lymphoblastoid B cells.

Authors:  J A Brieva; R A Martin; O Martinez-Maza; J Kagan; J Merrill; A Saxon; J Van Damme; R H Stevens
Journal:  Cell Immunol       Date:  1990-10-15       Impact factor: 4.868

6.  Fibronectin and VLA-4 in haematopoietic stem cell-microenvironment interactions.

Authors:  D A Williams; M Rios; C Stephens; V P Patel
Journal:  Nature       Date:  1991-08-01       Impact factor: 49.962

7.  Differential expression of VLA-4 integrin by resident and peripheral blood B lymphocytes. Acquisition of functionally active alpha 4 beta 1-fibronectin receptors upon B cell activation.

Authors:  A A Postigo; R Pulido; M R Campanero; A Acevedo; A García-Pardo; A L Corbi; F Sanchez-Madrid; M O De Landazuri
Journal:  Eur J Immunol       Date:  1991-10       Impact factor: 5.532

8.  Evidence for a role of the integrin VLA-4 in lympho-hemopoiesis.

Authors:  K Miyake; I L Weissman; J S Greenberger; P W Kincade
Journal:  J Exp Med       Date:  1991-03-01       Impact factor: 14.307

9.  The function of multiple extracellular matrix receptors in mediating cell adhesion to extracellular matrix: preparation of monoclonal antibodies to the fibronectin receptor that specifically inhibit cell adhesion to fibronectin and react with platelet glycoproteins Ic-IIa.

Authors:  E A Wayner; W G Carter; R S Piotrowicz; T J Kunicki
Journal:  J Cell Biol       Date:  1988-11       Impact factor: 10.539

10.  VLA-4 mediates CD3-dependent CD4+ T cell activation via the CS1 alternatively spliced domain of fibronectin.

Authors:  Y Nojima; M J Humphries; A P Mould; A Komoriya; K M Yamada; S F Schlossman; C Morimoto
Journal:  J Exp Med       Date:  1990-10-01       Impact factor: 14.307

View more
  26 in total

1.  Isolation, maturational level, and functional capacity of human colon lamina propria plasma cells.

Authors:  F Medina; C Segundo; A Campos-Caro; I Salcedo; A García-Poley; J A Brieva
Journal:  Gut       Date:  2003-03       Impact factor: 23.059

2.  Sustained secretion of immunoglobulin by long-lived human tonsil plasma cells.

Authors:  Jacob M van Laar; Marc Melchers; Y K Onno Teng; Boris van der Zouwen; Rozbeh Mohammadi; Randy Fischer; Leonid Margolis; Wendy Fitzgerald; Jean-Charles Grivel; Ferdinand C Breedveld; Peter E Lipsky; Amrie C Grammer
Journal:  Am J Pathol       Date:  2007-08-09       Impact factor: 4.307

3.  The ability of synoviocytes to support terminal differentiation of activated B cells may explain plasma cell accumulation in rheumatoid synovium.

Authors:  J Dechanet; P Merville; I Durand; J Banchereau; P Miossec
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

4.  c-Myb and Ets proteins synergize to overcome transcriptional repression by ZEB.

Authors:  A A Postigo; A M Sheppard; M L Mucenski; D C Dean
Journal:  EMBO J       Date:  1997-07-01       Impact factor: 11.598

5.  T cell-dependent survival of CD20+ and CD20- plasma cells in human secondary lymphoid tissue.

Authors:  David R Withers; Claudia Fiorini; Randy T Fischer; Rachel Ettinger; Peter E Lipsky; Amrie C Grammer
Journal:  Blood       Date:  2007-02-13       Impact factor: 22.113

6.  Bone marrow is a major site of long-term antibody production after acute viral infection.

Authors:  M K Slifka; M Matloubian; R Ahmed
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

7.  Expression and functional significance of alternatively spliced CS1 fibronectin in rheumatoid arthritis microvasculature.

Authors:  M J Elices; V Tsai; D Strahl; A S Goel; V Tollefson; T Arrhenius; E A Wayner; F C Gaeta; J D Fikes; G S Firestein
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

Review 8.  Homing behaviour of the malignant cell clone in multiple myeloma.

Authors:  I Van Riet; K Vanderkerken; C de Greef; B Van Camp
Journal:  Med Oncol       Date:  1998-09       Impact factor: 3.064

Review 9.  Plasma cell biology: Foundations for targeted therapeutic development in transplantation.

Authors:  Amy P Rossi; Rita R Alloway; David Hildeman; E Steve Woodle
Journal:  Immunol Rev       Date:  2021-07-12       Impact factor: 10.983

10.  Induction of programmed cell death in human hematopoietic cell lines by fibronectin via its interaction with very late antigen 5.

Authors:  H Sugahara; Y Kanakura; T Furitsu; K Ishihara; K Oritani; H Ikeda; H Kitayama; J Ishikawa; K Hashimoto; Y Kanayama
Journal:  J Exp Med       Date:  1994-06-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.